Skip to main content
SpringerLink
Log in

Cutaneous Manifestations of Renal Disease

  • Chapter
  • First Online:
Book cover Atlas of Dermatology in Internal Medicine

  • 3051 Accesses

Abstract

Chronic kidney disease (CKD) is very common among ­internal medicine patients. In the majority of cases, the skin is affected in some way. In this chapter, we discuss some of the cutaneous signs and symptoms associated with CKD, as well as some of the cutaneous syndromes. The clinical and histological features, pathogenesis, diagnostic evaluation, and management of uremic pruritus, calciphylaxis, benign nodular calcification, nephrogenic systemic fibrosis, and bullous disease of hemodialysis are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rosenthal SR. Uremic dermatitis. Arch Dermatol Syphil. 1931;23:934.

    Google Scholar 

  2. Cawley EP, Hoch-Ligeti C, Bond GM. The eccrine seat glands of patients in uremia. Arch Dermatol. 1961;84:51.

    Google Scholar 

  3. Sweeney S, Cropley TG. Cutaneous changes in renal disorders. Fitzpatrick’s dermatology in general medicine, vol. 2. 6th ed. New York: McGraw-Hill; 2003.

    Google Scholar 

  4. Masmoudi A, Ben Hmida M, Mseddi M, Meziou TJ, Walha N, Hachicha J, et al. Cutaneous manifestations of chronic hemodialysis. Prospective study of 363 cases. Presse Med. 2006;35(3 Pt 1):399–406.

    PubMed  Google Scholar 

  5. Sweeney S, Cropley TG. Cutaneous changes in renal disorders. Fitzpatrick’s dermatology in general medicine, vol. 2. 6th ed. New York: McGraw-Hill; 2003.

    Google Scholar 

  6. Nunley JR. Dermatologic manifestations of renal disease. Emedicine. http://www.emedicine.com. Accessed 16 Sept 2007.

  7. Ponticelli C, Bencini PL. Pruritus in dialysis patients: a neglected problem [editorial]. Nephrol Dial Transplant. 1995;10:2174.

    PubMed  CAS  Google Scholar 

  8. Stahle-Backdahl M. Uremic pruritus: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh). 1989;145:1.

    CAS  Google Scholar 

  9. Mettang T, Fritz P, Weber J, et al. Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD): the role of plasma histamine and skin mast cells. Clin Nephrol. 1990;34:136.

    PubMed  CAS  Google Scholar 

  10. Zucker I, Yosipovitch G, David M, Gafter U. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol. 2003;49:842.

    PubMed  Google Scholar 

  11. Pisoni RL, Wikstrom B, Elder SJ, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006;21:3495.

    PubMed  Google Scholar 

  12. Narita I, Iguchi S, Omori K, Gejyo F. Uremic pruritus in chronic hemodialysis patients. J Nephrol. 2008;21:161–5.

    PubMed  Google Scholar 

  13. De Marchi S, Cecchin E, Villalta D, et al. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med. 1992;326:969.

    PubMed  Google Scholar 

  14. Cohen EP, Russell TJ, Garancis JC. Mast cells and calcium in severe uremic itching. Am J Med Sci. 1992;303:360.

    PubMed  CAS  Google Scholar 

  15. Kessler M, Moneret-Vautrin DA, Cao-Huu T, et al. Dialysis pruritus and sensitization. Nephron. 1992;60:241.

    PubMed  CAS  Google Scholar 

  16. Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996;348:1552.

    PubMed  CAS  Google Scholar 

  17. Hampers CL, Katz AI, Wilson RE, Merrill JP. Disappearance of “uremic” itching after subtotal parathyroidectomy. N Engl J Med. 1968;279:695.

    PubMed  CAS  Google Scholar 

  18. Rosenthal SR. Uremic dermatitis. Arch Dermatol Syphil. 1931;23:934.

    Google Scholar 

  19. Cawley EP, Hoch-Ligeti C, Bond GM. The eccrine sweat glands of patients in uremia. Arch Dermatol. 1961;84:51.

    Google Scholar 

  20. Massry SG, Popovtzer MM, Coburn JW, et al. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N Engl J Med. 1968;279:697.

    PubMed  CAS  Google Scholar 

  21. Duque MI, Thevarajah S, Chan YH, et al. Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol. 2006;66:184.

    PubMed  CAS  Google Scholar 

  22. Narita I, Alchi B, Ornori K, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006;69:1626.

    PubMed  CAS  Google Scholar 

  23. Hiroshige K, Kabashima N, Takasugi M, Kuroiwa A. Optimal dialysis improves uremic pruritus. Am J Kidney Dis. 1995;25:413.

    PubMed  CAS  Google Scholar 

  24. Friga V, Linos A, Linos DA. Is aluminum toxicity responsible for uremic pruritus in chronic hemodialysis patients? Nephron. 1997;75:48.

    PubMed  CAS  Google Scholar 

  25. Mettang T, Pauli-Magnus C, Kuhlmann U. “Sick-bag” syndrome [letter]. Perit Dial Int. 2000;20:243.

    PubMed  CAS  Google Scholar 

  26. Noordzij M, Boeschoten EW, Bos WJ, for the NECOSAD Study Group, et al. Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients. Nephrol Dial Transplant. 2007;22(10):2944–9.

    PubMed  CAS  Google Scholar 

  27. Ada S, Seckin D, Budakoglu I, Ozdemir FN. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study. J Am Acad Dermatol. 2005;53:149.

    PubMed  Google Scholar 

  28. Balaskas EV, Uldall RP. Erythropoietin treatment does not improve uremic pruritus. Perit Dial Int. 1992;12:330.

    PubMed  CAS  Google Scholar 

  29. Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol. 2000;11:514.

    PubMed  CAS  Google Scholar 

  30. Wikstrom B, Gellert R, Ladefoged SD, et al. {kappa}-Opioid ­system in uremic pruritus: multicenter, randomized, double-blind. placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16:3742.

    PubMed  Google Scholar 

  31. Cho YL, Liu HN, Huang TP, Tarng DC. Uremic pruritus: role of parathyroid hormone and substance P. J Am Acad Dermatol. 1997;36:538.

    PubMed  CAS  Google Scholar 

  32. Yoshimoto-Furuie K, Yoshimoto K, Tanaka T, et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron. 1999;81:151.

    PubMed  CAS  Google Scholar 

  33. Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004;19:3137.

    PubMed  CAS  Google Scholar 

  34. Layegh P, Mojahedi MJ, Malekshah PE, Pezeshkpour F, Vahedian M, Nazemian F, et al. Effect of oral granisetron in uremic pruritus. Indian J Dermatol Venereol Leprol. 2007;73(4):231–4.

    PubMed  Google Scholar 

  35. Aucella F, Vigilante M, Gesuete A, Maruccio G, Specchio A, Gesualdo L. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role? Nephrol Dial Transplant. 2007;22 Suppl 5:v8–12.

    PubMed  CAS  Google Scholar 

  36. Aoike I. Clinical significance of protein adsorbable membranes – long-term clinical effects and analysis using a proteomic technique. Nephrol Dial Transplant. 2007;22 Suppl 5:v13–9.

    PubMed  CAS  Google Scholar 

  37. Makhlough A. Topical capsaicin therapy for uremic pruritus in patients on hemodialysis. Iran J Kidney Dis. 2010;4:137–40.

    PubMed  Google Scholar 

  38. Walsh JS, Fairley JA. Calcifying disorders of the skin. J Am Acad Dermatol. 1995;33:693–706.

    PubMed  CAS  Google Scholar 

  39. Robinson-Bostom L, Digiovanna JJ. Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol. 2000;43(6):975.

    PubMed  CAS  Google Scholar 

  40. Taylor EN, Henderson JM, Rennke HG, Magee CC. Traumatic calcinosis cutis in a dialysis patient. Am J Kidney Dis. 2004;44(2):e18–21.

    PubMed  Google Scholar 

  41. Van Haren FM, Ruiter DJ, Hillbrands LB. Nadroparin-induced calcinosis cutis in renal transplant recipients. Nephron. 2001;87(3):279–82.

    PubMed  Google Scholar 

  42. Eich D, Scharffetter-Kochanek K, Weihrauch J, Krieg T, Hunzelmann N. Calcinosis of the cutis and subcutis: an unusual nonimmunologic adverse reaction to subcutaneous injections of low-molecular-weight calcium-containing heparins. J Am Acad Dermatol. 2004;50(2):210–4.

    PubMed  Google Scholar 

  43. Nunley JR, Joness LM. Calcinosis cutis. http://www.emedicine.com.

  44. Gupta RK, Naran S, Cheung YK. Fine-needle aspiration cytology of soft tissue calcinosis presenting as an enlarging mass in the chest wall. Diagn Cytopathol. 1998;19(6):465–7.

    PubMed  CAS  Google Scholar 

  45. Solans EP, Bakhos R, Castelli MJ, Gattuso P. Fine needle aspiration biopsy of calcinosis cutis. A case report. Acta Cytol. 1997;41(2):590–2.

    PubMed  CAS  Google Scholar 

  46. Deshpande A, Munshi M. Calcinosis cutis: diagnosis by aspiration cytology – a case report. Diagn Cytopathol. 1999;21(3):200–2.

    PubMed  CAS  Google Scholar 

  47. Abdallah-Lotf M, Grasland A, Vinceneux P, Sigal-Grinberg M. Regression of cutis calcinosis with diltiazem in adult dermatomyositis. Eur J Dermatol. 2005;15(2):102–4.

    PubMed  CAS  Google Scholar 

  48. Palamaras J, Kyriakis K. Calcium antagonists in dermatology: a review of the evidence and research-based studies. Dermatol Online J. 2005;11(2):8.

    PubMed  Google Scholar 

  49. Palmieri GM, Sebes JL, Aelion JA, Moinuddin M, Ray MW, Wood GC, et al. Treatment of calcinosis with diltiazem. Arthritis Rheum. 1995;38(11):1646–54.

    PubMed  CAS  Google Scholar 

  50. Grasses F, Perello J, Isern B, Prieto RM. Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinois cutis. Br J Dermatol. 2005;152(5):1022–5.

    Google Scholar 

  51. Grasses F, Perello J, Isern B, Prieto RM. Study of the absorption of myo-inositol hexakisphosphate (InsP6) through the skin. Biol Pharm Bull. 2005;28(4):764–7.

    Google Scholar 

  52. Santos PW, Hartle JE, Quarles LD. Calciphylaxis. http://www.UpToDate.com. Accessed 19 Aug 2007.

  53. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61:2210.

    PubMed  Google Scholar 

  54. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122:1083.

    PubMed  CAS  Google Scholar 

  55. Adrogue HJ, Frazier MR, Zeluff B, Suki WN. Systemic calciphylaxis revisited. Am J Nephrol. 1981;1:177.

    PubMed  CAS  Google Scholar 

  56. Kent RB, Lylerly RT. Systemic calciphylaxis. South Med J. 1994;87:278.

    PubMed  Google Scholar 

  57. Perloff LJ, Spence RK, Grossman RA, Barker CF. Lethal post-transplantation calcinosis. Transplantation. 1979;27:21.

    PubMed  CAS  Google Scholar 

  58. Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failure. Am J Kidney Dis. 2000;35:588.

    PubMed  CAS  Google Scholar 

  59. Rezaie W, Overtoom HA, Flens M, Klaassen RJ. Calciphylaxis in chronic renal failure: an approach to risk factors. Indian J Nephrol. 2009;19:115–8.

    PubMed  CAS  Google Scholar 

  60. Goyal S, Huhn KM, Provost TT. Calciphylaxis in a patient without renal failure or elevated parathyroid hormone: possible aetiological role of chemotherapy. Br J Dermatol. 2000;143:1087.

    PubMed  CAS  Google Scholar 

  61. Riegert-Johnson DL, Kaur JS, Pfeifer EA. Calciphylaxis associated with cholangiocarcinoma treated with low-molecular-weight heparin and vitamin K. Mayo Clin Proc. 2001;76:749.

    PubMed  CAS  Google Scholar 

  62. Barri YM, Graves GS, Knochel JP. Calciphylaxis in a patient with Crohn’s disease in the absence of end-stage renal disease. Am J Kidney Dis. 1997;29:773.

    PubMed  CAS  Google Scholar 

  63. Korkmaz C, Dundar E, Zubaroglu I. Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of long-term steroid use and protein S deficiency. Clin Rheumatol. 2002;21:66.

    PubMed  CAS  Google Scholar 

  64. Pollock B, Cunliffe WJ, Merchant WJ. Calciphylaxis in the absence of renal failure. Clin Exp Dermatol. 2000;25:389.

    PubMed  CAS  Google Scholar 

  65. James LR, Lajoie G, Prajapati D, et al. Calciphylaxis precipitated by ultraviolet light in a patient with end-stage renal disease secondary to systemic lupus erythematosus. Am J Kidney Dis. 1999;34:932.

    PubMed  CAS  Google Scholar 

  66. Igaki N, Moriguchi R, Hirota Y, et al. Calciphylaxis in a patient with end-stage renal disease secondary to systemic lupus erythematosus associated with acral gangrene and mesenteric ischemia. Intern Med. 2001;40:1232.

    PubMed  CAS  Google Scholar 

  67. Sakr SH, Russell EB, Jasin HE. Systemic lupus erythematosus and calciphylaxis. J Rheumatol. 2004;31:1851.

    PubMed  Google Scholar 

  68. Adrogue HJ, Frazier MR, Zeluff B, Suki WN. Systemic calciphylaxis revisited. Am J Nephrol. 1981;1:177–83.

    PubMed  CAS  Google Scholar 

  69. Essary LR, Wick MR. Cutaneous calciphylaxis. An under recognized clinicopathologic entity. Am J Clin Pathol. 2000;113:280.

    PubMed  CAS  Google Scholar 

  70. Bleibel W, Hazar B, Herman R. A case report comparing various radiological tests in the diagnosis of calcific uremic arteriolopathy. Am J Kidney Dis. 2006;48:659.

    PubMed  Google Scholar 

  71. Wong JJ, Laumann A, Martinez M. Calciphylaxis and antiphospholipid antibody syndrome. J Am Acad Dermatol. 2000;42:849.

    PubMed  CAS  Google Scholar 

  72. Fischer AH, Morris DJ. Pathogenesis of calciphylaxis: study of three cases with literature review. Hum Pathol. 1995;26:1055.

    PubMed  CAS  Google Scholar 

  73. Rostaing L, el Feki S, Delisle MB, et al. Calciphylaxis in a chronic hemodialysis patient with protein S deficiency. Am J Nephrol. 1995;15:524.

    PubMed  CAS  Google Scholar 

  74. Mehta RL, Scott G, Sloand JA, Francis CW. Skin necrosis associated with acquired protein C deficiency in patients with renal ­failure and calciphylaxis. Am J Med. 1990;88:252.

    PubMed  CAS  Google Scholar 

  75. Heiss A, DuChesne A, Denecke B, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003;278:13333.

    PubMed  CAS  Google Scholar 

  76. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112:357.

    PubMed  Google Scholar 

  77. Price PA, Williamson MK, Nguyen TM, Than TN. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem. 2004;279:1594.

    PubMed  CAS  Google Scholar 

  78. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827.

    PubMed  CAS  Google Scholar 

  79. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78.

    PubMed  CAS  Google Scholar 

  80. Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells – a cell system which resembles the system in bone cells. Thromb Haemost. 1999;82:1764.

    PubMed  CAS  Google Scholar 

  81. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998;32:384.

    PubMed  CAS  Google Scholar 

  82. Roe SM, Grahan LD, Brock WB, Barker DE. Calciphylaxis: early recognition and management. Am Surg. 1994;60:81.

    PubMed  CAS  Google Scholar 

  83. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol. 2000;54:318.

    PubMed  CAS  Google Scholar 

  84. Bleyer AJ, White WL, Choi MJ. Calcific small vessel ischemic disease (calciphylaxis) in dialysis patients [editorial]. Int J Artif Organs. 2000;23:351.

    PubMed  CAS  Google Scholar 

  85. Russell R, Brookshire MA, Zekonis M, Moe SM. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care. Clin Nephrol. 2002;58:238.

    PubMed  CAS  Google Scholar 

  86. Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol. 2003;59:463.

    PubMed  CAS  Google Scholar 

  87. Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet – an alternative to parathyroidectomy? Nephrol Dial Transplant. 2006;21:1999.

    PubMed  Google Scholar 

  88. Robinson MR, Augustine JJ, Korman NJ. Cinacalcet for the treatment of calciphylaxis. Arch Dermatol. 2007;143:152.

    PubMed  Google Scholar 

  89. Sharma A, Burkitt-Wright E, Rustom R. Cinacalcet as an adjunct in the successful treatment of calciphylaxis. Br J Dermatol. 2006;155:1295.

    PubMed  CAS  Google Scholar 

  90. Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant. 2006;21:1999.

    PubMed  Google Scholar 

  91. Kang AS, McCarthy JT, Rowland C, et al. Is calciphylaxis best treated surgically or medically? Surgery. 2000;128:967.

    PubMed  CAS  Google Scholar 

  92. Girotto JA, Harmon JW, Ratner LE, et al. Parathyroidectomy ­promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery. 2001;130:645.

    PubMed  CAS  Google Scholar 

  93. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004;43:1104.

    PubMed  Google Scholar 

  94. Brucculeri M, Cheigh J, Bauer G, Serur D. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial. 2005;18:431.

    PubMed  Google Scholar 

  95. Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant. 2005;20:1260.

    PubMed  Google Scholar 

  96. Aray CE, Fennell RS, Neiberger RE, Dharnidharka VR. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol. 2006;1:1161.

    Google Scholar 

  97. Meissner M, Kaufmann R, Gille J. Sodium thiosulfate: a new way of treatment for calciphylaxis? Dermatology. 2007;214:278–82.

    PubMed  CAS  Google Scholar 

  98. Monney P, Nguyen QV, Perroud H, Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant. 2004;19:2130.

    PubMed  Google Scholar 

  99. Podymow T, Wherrett C, Burns KD. Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant. 2001;16:2176.

    PubMed  CAS  Google Scholar 

  100. Basile C, Montanaro A, Masi M, et al. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol. 2002;15:676.

    PubMed  Google Scholar 

  101. Centers for Disease Control and Prevention (CDC). Fibrosing skin condition among patients with renal disease – United States and Europe, 1997–2002. MMWR Morb Mortal Wkly Rep. 2002;51:25.

    Google Scholar 

  102. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000.

    PubMed  CAS  Google Scholar 

  103. Hubbard V, Davenport A, Jarmulowicz M, Rustin M. Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol. 2003;148:563.

    PubMed  CAS  Google Scholar 

  104. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol. 2006;18:614.

    PubMed  Google Scholar 

  105. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Website]. 2001–2007. http://www.icnfdr.org. Accessed 8 Sept 2007.

  106. Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol. 2006;21:1307.

    PubMed  Google Scholar 

  107. Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathologic exercises. Case 35-2004. A 68 year-old man with end-stage renal disease and thickening of the skin. N Eng J Med. 2004;351:2219.

    CAS  Google Scholar 

  108. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis. 2005;46:754.

    PubMed  Google Scholar 

  109. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:785.

    PubMed  Google Scholar 

  110. Cowper SE, Bucala R, LeBoit PE. Case 35-2004: nephrogenic fibrosing dermopathy. N Engl J Med. 2005;352:1723.

    PubMed  CAS  Google Scholar 

  111. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50:2660.

    PubMed  CAS  Google Scholar 

  112. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359.

    PubMed  Google Scholar 

  113. Edsall LC, English 3rd JC, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol. 2004;31:247.

    PubMed  Google Scholar 

  114. Samtleben W. Nephrogenic systemic fibrosis. Radiologe. 2007;47(9):778–84.

    PubMed  CAS  Google Scholar 

  115. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238.

    PubMed  Google Scholar 

  116. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve. 2004;30:569.

    PubMed  Google Scholar 

  117. Ting WW, Stone MS, Madison KC, et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903.

    PubMed  Google Scholar 

  118. Kucher C, Steere J, Elenitsas R, et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol. 2006;54:S31.

    PubMed  Google Scholar 

  119. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med. 2006;120:209.

    Google Scholar 

  120. Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563.

    PubMed  Google Scholar 

  121. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis- setting the record straight. Semin Arthritis Rheum. 2006;35:208.

    PubMed  Google Scholar 

  122. Jennifer OB, Maize JC, Woolson RF, Bodisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant. 2007; 22:3179–3185.

    Google Scholar 

  123. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2(2):264–7.

    PubMed  Google Scholar 

  124. Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104.

    PubMed  CAS  Google Scholar 

  125. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359.

    PubMed  Google Scholar 

  126. http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm.

  127. Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: a review of experimental data. World J Radiol. 2010;2:427–33.

    PubMed  Google Scholar 

  128. Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging. 2007;2(4):199–205.

    PubMed  CAS  Google Scholar 

  129. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148.

    PubMed  Google Scholar 

  130. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21.

    PubMed  Google Scholar 

  131. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in ­nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27.

    PubMed  Google Scholar 

  132. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller 3rd ER, Semelka RC. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy – report from two U.S. universities. Radiology. 2009;253:689–96.

    PubMed  Google Scholar 

  133. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243(1):148–57.

    PubMed  Google Scholar 

  134. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol. 2007;18(10):2636–43.

    PubMed  CAS  Google Scholar 

  135. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006;145:234.

    PubMed  Google Scholar 

  136. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant. 2006;6:2212.

    PubMed  CAS  Google Scholar 

  137. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003;25:204.

    PubMed  Google Scholar 

  138. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383.

    PubMed  CAS  Google Scholar 

  139. Edsall LC, English 3rd JC, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol. 2004;31:247.

    PubMed  Google Scholar 

  140. Miskulin D, Gul A, Rudnick M, Cowper S. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure. http://www.UpToDate.com. Accessed 22 Sept 2007.

  141. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: ­suspect identified, motive unclear. Am J Dermatopathol. 2003;25:358.

    PubMed  Google Scholar 

  142. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure – role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Nephrogenic systemic fibrosis: relationship to gadolinium and response. Clin J Am Soc Nephrol. 2007;2(2):258–63.

    PubMed  CAS  Google Scholar 

  143. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic ­systemic fibrosis: relationship to gadolinium and response to ­photopheresis. Arch Dermatol. 2007;143(8):1025–30.

    PubMed  Google Scholar 

  144. Kafi R, Fisher GJ, Quqan T, et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol. 2004;140:1322.

    PubMed  Google Scholar 

  145. Schmook T, Budde K, Ulrich C, et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant. 2005;20:220.

    PubMed  Google Scholar 

  146. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152:531.

    PubMed  CAS  Google Scholar 

  147. Lauchli S, Zortea-Caflisch C, Nestle FO, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004;208:278.

    PubMed  Google Scholar 

  148. Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest. 2000;106:663.

    PubMed  CAS  Google Scholar 

  149. Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure – role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2:258.

    PubMed  CAS  Google Scholar 

  150. Chung HJ, Chung KY. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol. 2004;150:596.

    PubMed  Google Scholar 

  151. http://www.fda.gov/cder/drug/advisory/gadolinum_agents.htm. Accessed 9 Sept 2007.

  152. Ryali ME, Whittier WL. Bullous skin lesions in a patient undergoing chronic hemodialysis. Semin Dial. 2010;23:83–7.

    PubMed  Google Scholar 

  153. Hebert AA, Farmer KL, Poh-Fitzpatrick MB. Peritoneal dialysis does not reduce serum porphyrin levels in porphyria cutanea tarda [letter]. Nephron. 1992;60:240.

    PubMed  CAS  Google Scholar 

  154. Seubert S, Seubert A, Rumpf KW, Kiffe H. A porphyria cutanea tarda-like distribution pattern of porphyrins in plasma, hemodialysate, hemofiltrate, and urine of patients on chronic hemodialysis. J Invest Dermatol. 1985;85:107.

    PubMed  CAS  Google Scholar 

  155. Kelly MA, O’Rourke KD. Treatment of porphyria cutanea tarda with phlebotomy in a patient on peritoneal dialysis. J Am Acad Dermatol. 2001;44:336.

    PubMed  CAS  Google Scholar 

  156. Stevens BR et al. Porphyria cutanea tarda in the setting of renal failure. Arch Dermatol. 1993;129:337.

    PubMed  CAS  Google Scholar 

  157. Sarkell B, Patterson JW. Treatment of porphyria cutanea tarda of end-stage renal disease with erythropoietin. J Am Acad Dermatol. 1993;29:499.

    PubMed  CAS  Google Scholar 

  158. Gilchrest B, Rowe JW, Mihm Jr MC. Bullous dermatosis of hemodialysis. Ann Intern Med. 1975;83(4):480–3.

    PubMed  CAS  Google Scholar 

  159. Griffon-Euvrard S, Thivolet J, Laurent G, et al. Detection of pseudo-porphyria cutanea tarda in 100 hemodialyzed patients (author’s transl). Dermatologica. 1977;155(4):193–9.

    PubMed  CAS  Google Scholar 

  160. Anderson KE, Goeger DE, Carson RW, et al. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med. 1990;322:315 [published erratum appears in N Engl J Med 1990; 322(22):1616.

    PubMed  CAS  Google Scholar 

  161. Yaqoob M, Smyth J, Ahmad R, et al. Haemodialysis-related porphyria cutanea tarda and treatment by recombinant human erythropoietin. Nephron. 1992;60:428.

    PubMed  CAS  Google Scholar 

  162. Peces R, Enriquez de Salamanca R, Fontanellas A, et al. Successful treatment of haemodialysis-related porphyria cutanea tarda with erythropoietin. Nephrol Dial Transplant. 1994;9:433.

    PubMed  CAS  Google Scholar 

  163. Carson RW, Dunnigan EJ, DuBose Jr TD, et al. Removal of plasma porphyrins with high-flux hemodialysis in porphyria cutanea tarda associated with end-stage renal disease. J Am Soc Nephrol. 1992;2:1445.

    PubMed  CAS  Google Scholar 

  164. Stockenhuber F, Kurz R, Grimm G, et al. Successful treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine. Nephron. 1990;55:321.

    PubMed  CAS  Google Scholar 

  165. Disler P, Day R, Burman N, et al. Treatment of hemodialysis-related Porphyria cutanea tarda with plasma exchange. Am J Med. 1982;72:989.

    PubMed  CAS  Google Scholar 

  166. Anderson KE et al. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med. 1990;322:315.

    PubMed  CAS  Google Scholar 

  167. Chazot C, Chazot I, Charra B, et al. Functional study of hands among patients dialysed for more than 10 years. Nephrol Dial Transplant. 1993;8(4):347–51.

    PubMed  CAS  Google Scholar 

  168. Griffon-Euvrard S, Thivolet J, Laurent G, et al. Detection of pseudo-porphyria cutanea tarda in 100 hemodialyzed patients (author’s transl). Dermatologica. 1977;155(4):193–9.

    PubMed  CAS  Google Scholar 

  169. Amblard P, Cordonnier D, Reymond JL, et al. Pseudo-pseudo-porphyria tarda in hemodialyzed patients. Ann Dermatol Venereol. 1981;108(12):1019–20.

    PubMed  CAS  Google Scholar 

  170. Gibson GE, McGinnity E, McGrath P, et al. Cutaneous ­abnormalities and metabolic disturbance of porphyrins in patients on maintenance haemodialysis. Clin Exp Dermatol. 1997;22(3):124–7.

    PubMed  CAS  Google Scholar 

  171. Poh-Fitzpatricks MB. Bullous disease of dialysis. http://www.emedicine.com. Accessed 19 Sept 2007.

  172. Poh-Fitzpatrick MB, Sosin AE, Bemis J. Porphyrin levels in plasma and erythrocytes of chronic hemodialysis patients. J Am Acad Dermatol. 1982;7(1):100–4.

    PubMed  CAS  Google Scholar 

  173. Gafter U, Mamet R, Korzets A, et al. Bullous dermatosis of ­end-stage renal disease: a possible association between abnormal porphyrin metabolism and aluminium. Nephrol Dial Transplant. 1996;11(9):1787–91.

    PubMed  CAS  Google Scholar 

  174. Schanbacher CF, Vanness ER, Daoud MS, et al. Pseudoporphyria: a clinical and biochemical study of 20 patients. Mayo Clin Proc. 2001;76:488–92.

    PubMed  CAS  Google Scholar 

  175. Sharp MT, Horn TD. Pseudoporphyria induced by voriconazole. J Am Acad Dermatol. 2005;53:341.

    PubMed  Google Scholar 

  176. Harvey E, Bell CH, Paller AS, et al. Pseudoporphyria cutanea tarda: two case reports on children receiving peritoneal dialysis and erythropoietin therapy. J Pediatr. 1992;121:749.

    PubMed  CAS  Google Scholar 

  177. Lim CK, Rideout JM, Peters TJ. Pseudoporphyria associated with consumption of brewers’ yeast. Br Med J (Clin Res Ed). 1984;288:1640.

    CAS  Google Scholar 

  178. Poh-Fitzpatrick MB. Porphyria, pseudoporphyria, pseudopseudoporphyria…? [editorial]. Arch Dermatol. 1986;122:403.

    PubMed  CAS  Google Scholar 

  179. Vadoud-Seyedi J, de Dobbeleer G, Simonart T. Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. Br J Dermatol. 2000;142(3):580–1.

    PubMed  CAS  Google Scholar 

  180. Massone C, Ambros-Rudolph CM, Di Stefani A, Müllegger RR. Successful outcome of haemodialysis-induced pseudoporphyria after short-term oral N-acetylcysteine and switch to high-flux technique dialysis. Acta Derm Venereol. 2006; 86(6):538–40.

    PubMed  Google Scholar 

  181. Cooke NS, McKenna K. A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine. Clin Exp Dermatol. 2007;32(1):64–6.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico

    Lilliam S. Chiqués Colón

  2. Department of Dermatology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico

    Rosbel González Rivera

Authors
  1. Lilliam S. Chiqués Colón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosbel González Rivera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lilliam S. Chiqués Colón .

Editor information

Editors and Affiliations

  1. and Dermatology and chairman, Department of Dermatology, Professor of Dermatopathology, Medical Sciences Campus School of Medicine, San Juan, 00931, Puerto Rico

    Néstor P. Sánchez

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Colón, L.S.C., Rivera, R.G. (2012). Cutaneous Manifestations of Renal Disease. In: Sánchez, N. (eds) Atlas of Dermatology in Internal Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0688-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-0688-4_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-0687-7

  • Online ISBN: 978-1-4614-0688-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation